译 Vir Biotechnology 和 GSK 启动 COVID-19 抗体的 2/3 期研究 Vir Biotechnology (NASDAQ:VIR) and GlaxoSmithKline plc (NYSE:GSK) announced that they have started dosing patients in a phase 2/3 clinical trial of VIR-7831 (or GSK4182136, as it's also known), a monoclonal antibody for early treatment of COVID-19 patients to prevent the disease from worsening ... The study, named COMET-ICE, will enroll 1,300 patients worldwide with mild or moderate COVID-19 who are at high risk of progression to severe symptoms ... Vir and GSK also plan to start a phase 2 trial later this year of a second antibody candidate, VIR-7832, that has similar characteristics to VIR-7831 but could also have preventative effects that would allow it to be used as a vaccine.
motley fool · Sep 1 3:17
译 为什么 Dynavax，Novavax 和 Vir Biotechnology 股票今天跳升 This bad news translated to good news for Dynavax, Novavax, and Vir as investors scooped up shares of the key players in the fight against the coronavirus ... So what Buying coronavirus-focused biotech stocks just because the pandemic appears to be worsening isn't a great idea without assessing the overall prospects for each individual stock ... Vir plans to advance its VIR-7831 and VIR-7832 antibody therapies for COVID-19 directly into phase 2 testing this summer pending FDA review.
motley fool · Jun 25 3:45
译 这就是为什么 Vir Biotechnology 在 5 月跃升 12％的原因 What happened Shares of Vir Biotechnology (NASDAQ:VIR) rose 12% in May, according to data provided by S&P Global Market Intelligence, after the biotech published preclinical data in the journal Nature on S309, a monoclonal antibody that appears to target SARS-CoV-2, the novel coronavirus that causes COVID-19 ... So what The S309 antibody was originally isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, but it appears that the structure of coronavirus responsible for SARS is close enough to that of the coronavirus that causes COVID-19 that the antibody can bind to both ... Vir is developing two treatments -- VIR-7831 and VIR-7832 -- based on the S309 antibody in collaboration with GlaxoSmithKline (NYSE:GSK).
motley fool · Jun 9 2:06
译 Vir 生物技术正在逆转生物技术 COVID-19 趋势，并有望获胜 By bucking the traditional wisdom regarding exclusivity and drug development, Vir has a real chance of entering the market sooner than competitors at a time when demand for its product would be enormously high ... There's more to Vir than COVID-19 If Vir brings one of its COVID-19 programs to market, it'll be one more addition to the company's impressive roster of therapies and prophylactics for viral diseases ... I'd recommend buying Vir shares now, to maximize the benefit of successive boosts to the company's stock price as its COVID-19 candidates pass through each phase of clinical trials.
motley fool · Jun 2 12:23
译 韩国三星生物药业（Samsung Biologics）与 GSK 签署 2.31 亿美元的供应协议 SEOUL, May 22 (Reuters) - South Korean contract drugs manufacturer Samsung Biologics Co Ltd (207940.KS) said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) (GSK.L) to supply biopharmaceutical products over the next eight years.
路透社 · May 22 10:00
译 为什么 Vir 生物技术今天飞速发展 Shares of Vir Biotechnology (NASDAQ:VIR) soared on Monday after the company announced some exciting news regarding its efforts to develop a treatment for COVID-19 ... Vir is collaborating with GlaxoSmithKline (NYSE:GSK) in this potentially lucrative project, and the two companies expect to start clinical testing this summer ... Given that a lot can go wrong for Vir in the meantime, it might be best to watch this one from the sidelines.
motley fool · May 19 5:00
译 Vir Biotechnology 和 Alnylam 选择冠状病毒疫苗候选者 The collaboration between Vir Biotechnology (NASDAQ:VIR) and Alnylam (NASDAQ:ALNY) that they expanded in March to address COVID-19 has selected a treatment candidate to advance into clinical trials ... The partners will seek accelerated approval from regulators to treat human volunteers with VIR-2703, also known as ALN-COV, which makes it hard for the SARS-CoV-2 coronavirus to reproduce ... The partners still aren't sure if they want to develop VIR-2703 as a treatment for patients with COVID-19
motley fool · May 4 10:23
译 Vir，Alnylam 确定了 COVID-19 治疗候选药物，并计划在年底之前进行人体试验 May 4 (Reuters) - Vir Biotechnology Inc (VIR.O) and Alnylam Pharmaceuticals Inc (ALNY.O) have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday. The companies plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss accelerating their filing for starting the trials of the inhaled therapy. Shares of Vir Biotech climbed 4% to $29, while Alnylam’s stock rose 1.6%
路透社 · May 4 8:20
译 Vir，Alnylam 选择冠状病毒治疗候选药物，并计划在年底之前进行人体试验 May 4 (Reuters) - Vir Biotechnology Inc (VIR.O) and Alnylam Pharmaceuticals Inc (ALNY.O) have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday. The therapy candidate makes use of gene-silencing RNA interference (RNAi) technology that targets and “silences” specific genetic material, blocking the production of deadly proteins that cause diseases.
路透社 · May 4 7:46